{"disease":{"id":"metastatic-gastric-cancer","name":"Metastatic Gastric Cancer","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":7,"pipeline_drug_count":0,"trial_count":2},"drugs":{"marketed":[{"drug_id":"capecitabine","indication_name":"Treatment of unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."},{"drug_id":"trastuzumab-anns","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"KANJINTI","generic_name":"TRASTUZUMAB-ANNS","company_name":"AMGEN INC","drug_phase":"marketed","molecular_target":"","drug_class":"HER2/neu Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"mitomycin","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mitozytrex","generic_name":"MITOMYCIN","company_name":"Kyowa Kirin Co., Ltd.","drug_phase":"marketed","molecular_target":"Indoleamine 2,3-dioxygenase 1","drug_class":"Alkylating Drug [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"adriacin","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"liposomal-doxorubicin","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"doxorubicin","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"hydroxydaunomycin","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07392892","title":"A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":840,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06342427","title":"Stomach Cancer Exosome-based Detection","phase":"","overall_status":"COMPLETED","enrollment_count":809,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT06324357","title":"Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":768,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT05038254","title":"Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":750,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT05714124","title":"Liver Embolization Approaches for Tumor Management","phase":"","overall_status":"RECRUITING","enrollment_count":580,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT03504397","title":"A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":565,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT02500043","title":"Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":507,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":true},{"nct_id":"NCT03653507","title":"A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":507,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT06901531","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT06177041","title":"M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":486,"lead_sponsor_name":"FutureGen Biopharmaceutical (Beijing) Co., Ltd","has_results":false},{"nct_id":"NCT05581004","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT02052778","title":"A Study of TAS-120 in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":407,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":true},{"nct_id":"NCT06427941","title":"A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":392,"lead_sponsor_name":"BeOne Medicines","has_results":false},{"nct_id":"NCT04358354","title":"Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":388,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT06902545","title":"A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.","phase":"","overall_status":"RECRUITING","enrollment_count":377,"lead_sponsor_name":"Astellas Pharma Korea, Inc.","has_results":false},{"nct_id":"NCT02625623","title":"Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":371,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT01285557","title":"Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":361,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":true},{"nct_id":"NCT04907643","title":"Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes","phase":"NA","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT05075993","title":"Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":352,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04248452","title":"Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":314,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT05620134","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":263,"lead_sponsor_name":"Salubris Biotherapeutics Inc","has_results":false},{"nct_id":"NCT02903914","title":"Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT06768463","title":"Cytoreductive Gastrectomy After Systemic Therapy Versus Systemic Therapy Alone For Limited Metastasis Gastric Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"University Medical Center Ho Chi Minh City (UMC)","has_results":false},{"nct_id":"NCT06877910","title":"Deciphering the Molecular Traits of Non-canonical Responders to Advance Personalized Therapy in Gastric Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":220,"lead_sponsor_name":"Regina Elena Cancer Institute","has_results":false},{"nct_id":"NCT01283204","title":"Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT06157892","title":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":172,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT07390838","title":"A Study of SH009 Injection in Patients With Advanced Solid Tumors.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04492488","title":"A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":129,"lead_sponsor_name":"Shanghai Miracogen Inc.","has_results":false},{"nct_id":"NCT06714617","title":"Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT05230771","title":"Clinical Outcome of Palliative Surgery After Translational Therapy for Metastatic Gastric Cancer Versus Maintenance Chemotherapy for Metastatic Gastric Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT03724851","title":"Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"MedPacto, Inc.","has_results":false},{"nct_id":"NCT04660760","title":"Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":116,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":false},{"nct_id":"NCT04189445","title":"Futibatinib in Patients With Specific FGFR Aberrations","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":115,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":true},{"nct_id":"NCT06730373","title":"First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT05472532","title":"Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture)","phase":"NA","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT04618809","title":"Improving the Approach to and Management of the Older Patient With Metastatic Gastric Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Fox Chase Cancer Center","has_results":false},{"nct_id":"NCT03409848","title":"Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT05765357","title":"Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT04068896","title":"Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"NGM Biopharmaceuticals, Inc","has_results":true},{"nct_id":"NCT04579757","title":"Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":87,"lead_sponsor_name":"Hutchmed","has_results":true},{"nct_id":"NCT03823144","title":"Intravital Microscopy in Human Solid Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04260802","title":"A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":73,"lead_sponsor_name":"Ocellaris Pharma, Inc.","has_results":false},{"nct_id":"NCT06147037","title":"A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03368963","title":"TAS102 in Combination With NAL-IRI in Advanced GI Cancers","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":64,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT03698825","title":"TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"MedPacto, Inc.","has_results":false},{"nct_id":"NCT05188209","title":"A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Shanghai Miracogen Inc.","has_results":false},{"nct_id":"NCT07341737","title":"SL-28 for Advanced Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Second Life Therapeutics","has_results":false},{"nct_id":"NCT04739202","title":"Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}